Look back at pharma news to Sept 8

10 September 2017

By Barbara Obstoj-Cardwell. Editor.

In the news last week was Sarepta Therapeutics with its Duchenne drug golodirsen, and AstraZeneca hit the limelight with news of disappointing results in its Mystic lung cancer trial of the PD-1/L1-plus-CTLA4 combination of Imfinzi (durvalumab) and tremelimumab. The news that Novartis chief executive Joseph Jimenez is to step down from the post grabbed a lot of comment. There was also disappointing news for Cellectis with its novel target for CAR-T cells, CD123 and positive results for Insmed’s Arikayce, but mixed for Alnylam’s hemophilia drug candidate fitusiran.

Sarepta unveils tentatively positive results in DMD

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK